From what 9 stock analysts predict, the share price for Bruker Corp (BRKR) might decrease by 1.55% in the next year. This is based on a 12-month average estimation for BRKR. Price targets go from $66.00 to $95.00. The majority of stock analysts believe BRKR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
BRKR is a stock in Industrials which has been forecasted to be worth $82.44 as an average. On the higher end, the forecast price is $95.00 USD by patrick b donnelly from Citi and on the lower end BRKR is forecasted to be $66.00 by matthew sykes from Goldman Sachs.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
matthew sykes Goldman Sachs | Sell | $66.0 | maintained | Feb 13, 2024 |
isaac ro Goldman Sachs | Sell | $15.0 | downgraded | Dec 18, 2014 |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
When did it IPO
0
Staff Count
8,525
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Frank H. Laukien Ph.D.
Market Cap
$11.34B
In 2023, BRKR generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BRKR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
EXAS-USD
$63.29
REG-USD
$60.81
AZPN-USD
$179.8
GTLB-USD
$70.18
AFRM-USD
$37.33
EVRG-USD
$50.61